drugset
drugset / Trial / NCT07408856

CAN1012 in Pre-Malignant DCIS and LCIS

NCT07408856 ↗

Phase 1 Not yet recruiting 24 enrolled Providence Health & Services CanWell Pharma Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase I/Ib study evaluating CAN1012 in patients with ductal carcinoma in situ and lobular carcinoma in situ.

Timeline

Start
2026-05
Primary completion
2030-05
Completion
2035-05

Drugs

EvaluationDrugModalityDoseRoute
Subject CAN1012 Unknown — Other

Indications

ductal breast carcinoma in situ lobular breast carcinoma in situ